A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Renovo Rx, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 26,195 shares of RNXT stock, worth $29,600. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,195
Holding current value
$29,600
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.02 - $1.46 $26,718 - $38,244
26,195 New
26,195 $29,000

Others Institutions Holding RNXT

About RenovoRx, Inc.


  • Ticker RNXT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 9,066,860
  • Market Cap $10.2M
  • Description
  • RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, In...
More about RNXT
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.